Novadip
Novel stem cell therapies for regenerative medicine using its unique 3M3 tissue regeneration platform
Novadip Biosciences is a biopharmaceutical company founded to design, develop and bring to the market innovative stem cell-based therapies for regenerative medicine. Novadip is a spin-off company from Université Catholique de Louvain and St. Luc University Hospital.
Using unique 3M3 tissue regeneration platform, which utilizes adipose-derived stem cells within a 3-dimensional extracellular matrix, to drive multiple product classes, Novadip’s mission is to provide innovative solutions for patients with limited or no effective treatment options.
Visit website: https://www.novadip.com/
Details last updated 06-Jul-2021
Novadip News
AgomAb raises €62M in Series B round to advance regenerative medicine
Labiotech - 16-Mar-2021
Funds to bring the experimental drug to trials; symbolizes booming regenerative niche
Read more...